Industry Veterans Will Introduce Breast Cancer Risk Stratifier to Help Physicians Determine Monitoring and Treatment Plans for Women with Intermediate Levels of Risk MOUNTAIN VIEW, Calif.–Perlegen Sciences, which develops genetic tests that correlate genetic variation to predisposition to disease and drug response, announced today that it has added key positions to its commercial team in […]
AUSTIN, Texas–Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, announced today that it has performed computer-based sequence analysis of the U.S. swine flu patient isolates and compared them to the primer sequences of the Company’s xTAG RVP assay. In the interest of providing information to its customers and to public health labs, Luminex […]
AUSTIN, Texas–Luminex Corporation (NASDAQ: LMNX – News), the worldwide leader in multiplexed solutions, today issued a follow-up statement to an announcement on Monday, April 27, 2009, confirming that the xTAG® Respiratory Viral Panel (RVP) assay has been demonstrated to be effective in surveillance of swine flu. Specifically, Luminex has verified through testing on confirmed swine […]
Agreement for Ahlstrom Grade 226 Dried Blood Spot Collection Delivers Added Consistency and Quality to Market WALTHAM, Mass.–PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it has entered into a contract with ID Biological Systems of Greenville, South Carolina, USA, to become its […]
Unique GeneXpert® System Capabilities Enable Powerful New TB Diagnostic Tool SUNNYVALE, Calif., April 27 — Cepheid (Nasdaq: CPHD – News) today announced the release of Xpert® MTB/RIF as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. For the first time, European clinicians will have access to a rapid […]
InforSense Accelerates and Automates Diagnostic Biomarker Discovery London, UK and Cambridge, MA, April, 27th, 2009 – InforSense Ltd., the leading provider of next generation business and scientific intelligence solutions, today announced that Celera Corporation, a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries, is using InforSense to […]
Genetic Analysis Patents and Cardiac Genetic Markers Key to Development of New Celera Tests MOUNTAIN VIEW, Calif.–Perlegen Sciences, which develops genetic tests that correlate genetic variation to predisposition to disease and drug response, announced today that it has entered a non-exclusive license agreement with Celera focused on a family of patents that covers methods of […]
Additional senior hires set the stage for global commercialization OTTAWA, ONTARIO–(April 22, 2009) – Spartan Bioscience Inc, a Canadian molecular diagnostics company that develops, manufactures, and markets DNA analyzers for on-demand applications, today announced management changes and the addition of several key staff. These additions to the Spartan team set the stage for accelerated growth […]
Mobile field clinics to provide cervical cancer screening to 50,000 women Venlo, The Netherlands / Kolkata, India, April 21, 2009 — QIAGEN and the Chittaranjan National Cancer Institute (CNCI) today announced a collaboration to establish the first large-scale cervical cancer screening program for women in Kolkata, India. QIAGEN (NASDAQ: QGEN, Frankfurt Prime Standard: QIA) will […]
DAYTONA, FL — 04/20/09 — 25th Clinical Virology Symposium — Seegene’s Seeplex® Meningitis ACE Detection test introduced today at the 2009 Clinical Virology Symposium brings a novel and fast-acting multiplex PCR diagnostic technique to simultaneously verify a complex range of pathogens that indicate meningitis, a severely debilitating infection that if not diagnosed and treated quickly […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
